- Home
- PHR
PHR
Phreesia Inc.
as 01-17-2025 4:00pm EST
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 1.6B | IPO Year: | 2019 |
| Target Price: | $30.92 | AVG Volume (30 days): | 359.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.07 - $29.16 | Next Earning Date: | 03-13-2025 |
| Revenue: | $405,137,000 | Revenue Growth: | 19.91% |
| Revenue Growth (this year): | 18.79% | Revenue Growth (next year): | 13.75% |
Stock Insider Trading Activity of Phreesia Inc. (PHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hui Yvonne | PHR | Principal Accounting Officer | Jan 10 '25 | Sell | $27.85 | 388 | $10,805.80 | 26,517 | |
| Hui Yvonne | PHR | Principal Accounting Officer | Jan 8 '25 | Sell | $28.00 | 288 | $8,064.00 | 26,517 | |
| VanDuyn Amy Beth | PHR | SVP, Human Resources | Jan 6 '25 | Sell | $26.61 | 1,311 | $34,879.81 | 115,633 | |
| Roberts Evan | PHR | Chief Operating Officer | Jan 6 '25 | Sell | $26.80 | 10,192 | $274,050.60 | 772,674 | |
| Linetsky David | PHR | SVP, Life Sciences | Jan 6 '25 | Sell | $26.61 | 3,133 | $83,355.03 | 239,211 | |
| Hoffman Allison C | PHR | General Counsel & Secretary | Jan 6 '25 | Sell | $26.61 | 3,982 | $105,943.10 | 159,137 | |
| Indig Chaim | PHR | Chief Executive Officer | Jan 6 '25 | Sell | $26.61 | 5,375 | $143,004.56 | 1,262,220 | |
| Gandhi Balaji | PHR | Chief Financial Officer | Jan 6 '25 | Sell | $26.61 | 3,195 | $85,004.57 | 148,509 | |
| Linetsky David | PHR | SVP, Life Sciences | Dec 18 '24 | Sell | $25.38 | 24 | $609.02 | 239,211 | |
| Hoffman Allison C | PHR | General Counsel & Secretary | Dec 18 '24 | Sell | $24.88 | 3,495 | $86,955.60 | 159,137 |
Latest Phreesia Inc. News
PHR Breaking Stock News: Dive into PHR Ticker-Specific Updates for Smart Investing
Argus Research
a day ago
Daily – Vickers Top Buyers & Sellers for 01/17/2025
Zacks
4 days ago
Phreesia (PHR) Upgraded to Buy: Here's Why
Simply Wall St.
8 days ago
Exploring High Growth Tech Stocks In The United States January 2025
MT Newswires
10 days ago
Phreesia Insider Sold Shares Worth $274,051, According to a Recent SEC Filing
Zacks
10 days ago
Should You Buy Phreesia (PHR) After Golden Cross?
MT Newswires
10 days ago
KeyBanc Raises Price Target on Phreesia to $30 From $28, Keeps Overweight Rating
MT Newswires
10 days ago
RBC Upgrades Phreesia to Outperform From Sector Perform, Raises Price Target to $32 From $24
Zacks
a month ago
Wall Street Analysts See a 25% Upside in Phreesia (PHR): Can the Stock Really Move This High?
Compare PHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHR Phreesia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.